A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
← catalyst calendarNCT07035093 · readout ≤ 407 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
586estimated
Sites
40
Countries
Argentina, Canada, Poland +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-29 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
- Chronic Low Back Pain (CLBP)
Interventions
- Drug: Retatrutide — also filed as LY3437943
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from Baseline in Pain Intensity Per Numeric Rating Scale
measured Baseline, up to 72 weeks
Percent Change from Baseline in Body Weight
measured Baseline, up to 72 weeks
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed